GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anxo Pharmaceutical Co Ltd (ROCO:6677) » Definitions » Earnings per Share (Diluted)

Anxo Pharmaceutical Co (ROCO:6677) Earnings per Share (Diluted) : NT$0.67 (TTM As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Anxo Pharmaceutical Co Earnings per Share (Diluted)?

Anxo Pharmaceutical Co's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was NT$0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.67.

Anxo Pharmaceutical Co's EPS (Basic) for the six months ended in Jun. 2023 was NT$0.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.68.

Anxo Pharmaceutical Co's EPS without NRI for the six months ended in Jun. 2023 was NT$0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was NT$0.67.

During the past 10 years, Anxo Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was -15.20% per year. The lowest was -15.20% per year. And the median was -15.20% per year.


Anxo Pharmaceutical Co Earnings per Share (Diluted) Historical Data

The historical data trend for Anxo Pharmaceutical Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anxo Pharmaceutical Co Earnings per Share (Diluted) Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.62 0.51 0.63 0.39 -0.25

Anxo Pharmaceutical Co Semi-Annual Data
Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.37 -0.79 0.54 0.13

Competitive Comparison of Anxo Pharmaceutical Co's Earnings per Share (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anxo Pharmaceutical Co's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Anxo Pharmaceutical Co's PE Ratio falls into.



Anxo Pharmaceutical Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Anxo Pharmaceutical Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-12.558-0)/49.939
=-0.25

Anxo Pharmaceutical Co's Earnings Per Share (Diluted) for the quarter that ended in Jun. 2023 is calculated as

Diluted Earnings Per Share (Q: Jun. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(6.516-0)/50.918
=0.13

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Anxo Pharmaceutical Co  (ROCO:6677) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Anxo Pharmaceutical Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Anxo Pharmaceutical Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Anxo Pharmaceutical Co (ROCO:6677) Business Description

Traded in Other Exchanges
N/A
Address
8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.

Anxo Pharmaceutical Co (ROCO:6677) Headlines

No Headlines